The components of explosive devices can be difficult to characterize, whether pre- or post-blast. To rectify this, ...

The Light Stage 3 (2002) was the first physical set to use an array of RGB LED lights surrounding an actor to create an ...

The nonlinear optical properties of BP/ReS2 heterojunction saturable absorber in 2 μm all-solid-state lasers was investigated ...

Finding new materials with useful properties is a primary goal for materials scientists, and it's central to improving ...

Neumora expects to report data from the Phase 1 SAD/MAD study in the first quarter of 2026, including safety and tolerability, and human pharmacokinetic data confirming the potential for once ...

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 Provided by GlobeNewswire Jul 9, 2025, 4:00:00 AM ...

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions ...

Explore the BHEL Artisan Syllabus 2025, including exam pattern, post-wise syllabus, prep tips, and other details on this page ...

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) ...

LumiThera’s photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD ...

LumiThera, Inc. is an ophthalmic medical device company that is Harnessing the Power of Light™ to offer a comprehensive approach for detecting, treating, and monitoring retinal diseases ...